Adverse predictive value of ASPM on lung adenocarcinoma overall survival depended on chemotherapy status.

OBJECTIVE

Transcriptome and proteome analyses may yield inconsistent predictions regarding tumor prognosis. The clinical and pathological significance of ASPM expression in lung adenocarcinoma (LUAD) remains unclear. This study investigates the expression and prognostic value of ASPM, focusing on its role in chemotherapy outcomes.

METHODS

We analyzed the prognostic relevance of ASPM using bioinformatics, immunohistochemical staining of LUAD tissue microarrays, and proteomics data. Further, in vitro experiments were conducted to evaluate the effects of ASPM overexpression on cell proliferation and sensitivity to cisplatin.

RESULTS

Bioinformatics analysis revealed that ASPM's prognostic significance differed between transcriptomic and proteomic datasets. Immunohistochemistry showed that high ASPM expression predicted improved overall survival only in LUAD patients undergoing chemotherapy, not in those without. Proteomics analysis identified ASPM-related signatures enriched in cell cycle and mitosis pathways. In vitro, ASPM overexpression promoted tumor cell proliferation and enhanced cisplatin-induced cytotoxicity.

CONCLUSION

ASPM exhibits a dual role in LUAD prognosis, acting as a marker for improved chemotherapy outcomes while promoting tumor proliferation. These findings underscore ASPM's potential as a therapeutic target and predictive marker for personalized treatment in LUAD.